Novel Pharmacological Treatment for Depression.
- Author:
Hee Jeong JEONG
1
;
Eunsoo MOON
Author Information
1. Department of Psychiatry, Pusan National University Hospital, Busan, Korea. esmun@hanmail.net
- Publication Type:Original Article
- Keywords:
Depressive disorder;
Treatment-resistant depression;
Novel antidepressant;
Pharmacotherapy
- MeSH:
Anti-Inflammatory Agents;
Antidepressive Agents;
Antidepressive Agents, Tricyclic;
Antioxidants;
Axis, Cervical Vertebra;
Cholinergic Antagonists;
Depression*;
Depressive Disorder;
Drug Therapy;
Galanin;
Glutamic Acid;
Monoamine Oxidase Inhibitors;
Neuropeptide Y;
Neuropeptides;
Norepinephrine;
Serotonin;
Serotonin Uptake Inhibitors
- From:Journal of the Korean Society of Biological Psychiatry
2016;23(1):1-11
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Development of various antidepressants such as monoamine oxidase inhibitors, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and noradrenergic and specific serotonergic antidepressant has led to a tremendous progression of pharmaceutical treatment for depression, but still there are some limitations of current antidepressants, such as treatment-resistant depression and delayed onset of antidepressants. The pathogenesis of depression is unclear because depression is a heterogeneous disease state, and the mechanisms of antidepressants remain uncertain as well. Nevertheless, in an attempt to develop novel antidepressants, some trials have been conducted based on the potential biological mechanism discovered in the numerous research results. This review will provide information about the potential novel antidepressants and the current states of clinical studies using them. In particular, some potential novel antidepressants anti-inflammatory agents, antioxidants, anticholinergics, modulators of Hypothalamic Pituitary Adrenal Axis, glutamate, and opioid systems, as well as some neuropeptides such as susbstance P, neuropeptide Y, and galanin will be discussed.
